Form 4: Gilead EVP's Stock & Option Activity Reported

Gilead Sciences EVP Keeley M. Cain Wettan reported acquisition of common stock, restricted stock units, and non-qualified stock options, alongside a tax-related disposal of shares.

Summary

• Keeley M. Cain Wettan, EVP Gen Counsel, Legal & Comp at Gilead Sciences, Inc. (GILD), reported transactions on March 10, 2026.
• Acquired 1,246 shares of common stock through the vesting of restricted stock units.
• Disposed of 606 shares of common stock at a price of $148.56 per share, likely for tax withholding purposes related to the vesting.
• Beneficially owns 5,054 shares of common stock directly following these transactions.
• Acquired 1,246 restricted stock units (RSUs) through vesting.
• Received a new grant of 5,050 restricted stock units (RSUs).
• Beneficially owns 20,586 restricted stock units directly following these transactions.
• Received a new grant of 18,885 non-qualified stock options with an exercise price of $148.56.
• The stock options have an expiration date of March 10, 2036.
• Beneficially owns 18,885 non-qualified stock options directly following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents routine executive compensation activity, including the vesting of prior awards and the grant of new long-term incentives, which is standard practice and does not indicate a significant change in company fundamentals or outlook.

Positives

• Acquisition of 1,246 shares of common stock through the vesting of restricted stock units, increasing direct equity ownership.
• Grant of 5,050 new restricted stock units, representing future equity potential.
• Grant of 18,885 non-qualified stock options, providing long-term incentive and potential for future gains.

Negatives

• Disposal of 606 shares of common stock, reducing direct share ownership, although this was likely for tax purposes related to vesting.

Future Outlook

The restricted stock units and non-qualified stock options granted have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested. This indicates a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity grants like restricted stock units and stock options, is a standard practice in the biopharmaceutical industry. These grants are designed to align executive interests with shareholder value creation over the long term, a common strategy among peers like Pfizer, Merck, and Johnson & Johnson.

Comparison to Industry Standards

• The four-year vesting schedule for both RSUs and stock options is a common industry standard for executive equity compensation, comparable to practices at major pharmaceutical companies such as Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK).
• The grant of non-qualified stock options with a 10-year expiration date (until March 10, 2036) is also typical for long-term incentive plans in the sector, aiming to retain talent and incentivize sustained performance.

Stakeholder Impact

• Shareholders: The grants of RSUs and stock options align executive incentives with shareholder value over the long term, potentially benefiting shareholders if the company performs well.
• Employees: This filing specifically relates to an executive's compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy.

Next Steps

• The restricted stock units and non-qualified stock options will vest over a four-year period, with 25% vesting on the first anniversary of the grant date and 6.25% quarterly thereafter.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of equity awards and new grants of restricted stock units and stock options. Such transactions are standard and do not typically signal a change in the company's operational performance or strategic direction. Therefore, a seasoned investor would likely maintain their current position based solely on this filing, awaiting more substantive corporate news or financial results.

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation, Common Stock